ArriVent BioPharma
AVBP
AVBP
139 hedge funds and large institutions have $969M invested in ArriVent BioPharma in 2026 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 57 increasing their positions, 28 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
15% more funds holding
Funds holding: 121 → 139 (+18)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
1.92% less ownership
Funds ownership: 97.14% → 95.22% (-1.9%)
Holders
139
Holding in Top 10
5
Calls
$12.3M
Puts
$3.56M
Top Buyers
| 1 | +$20M | |
| 2 | +$12M | |
| 3 | +$8.66M | |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$7.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$7.44M |
Top Sellers
| 1 | -$15.5M | |
| 2 | -$13M | |
| 3 | -$6.6M | |
| 4 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$4.88M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.79M |
